ScienceWeight loss and semaglutide’s cardiovascular benefit in the SELECT trial
A post sharing a SELECT trial analysis says Ozempic’s cardiovascular benefit in the large randomized trial was substantially unrelated to weight loss.
TLDR
A post highlighting a mediation analysis of SELECT says Ozempic’s cardiovascular benefit in the large randomized trial was substantially unrelated to weight loss. The linked paper’s abstract describes weekly injected semaglutide, at a target dose of 2.4 mg, in adults with pre-existing cardiovascular disease.
Weight loss and semaglutide’s cardiovascular benefit in the SELECT trial
A post sharing a SELECT trial analysis says Ozempic’s cardiovascular benefit in the large randomized trial was substantially unrelated to weight loss.
TLDR
A post highlighting a mediation analysis of SELECT says Ozempic’s cardiovascular benefit in the large randomized trial was substantially unrelated to weight loss. The linked paper’s abstract describes weekly injected semaglutide, at a target dose of 2.4 mg, in adults with pre-existing cardiovascular disease.
